Welcome to our dedicated page for USANA HEALTH SCIENCES SEC filings (Ticker: USNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
USANA Health Sciences, Inc. filings document financial results, management commentary and Regulation FD disclosures for a health and wellness products company. Form 8-K reports cover quarterly and annual results, preliminary sales information, guidance, exhibits and conference-call materials tied to the company’s operating updates.
Proxy and governance filings address director elections, board matters, executive compensation, equity awards and pay-versus-performance disclosure. Other material-event reports document leadership changes, transition agreements and compensatory arrangements, providing formal records of governance and management structure for USANA Health Sciences.
USANA Health Sciences director John Turman Fleming reported the conversion of 1,632 Restricted Stock Units into 1,632 shares of common stock on July 23, 2026. After this derivative exercise, he directly holds 5,862 common shares and 4,895 Restricted Stock Units, which vest 25% on July 23, 2026, October 22, 2026, January 21, 2027, and April 22, 2027.
USANA Health Sciences director Xia Ding reported equity compensation activity on July 23, 2026. Ding exercised 1,632 restricted stock units, receiving the same number of common shares. Also on that date, 604 shares at $20.92 per share were withheld to satisfy the exercise price or tax liability, and 4,895 restricted stock units are reported as directly held afterward.
USANA Health Sciences Chief Commercial Officer Brent Neidig reported an open-market sale of 5,002 shares of Common Stock. The shares were sold at a weighted average price of $19.453 per share, with individual trade prices ranging from $19.35 to $19.68.
Following this transaction, Neidig reported direct ownership of 0 shares of USANA Common Stock.
Reported insider sale by Brent Lowell Neidig. The filing discloses dispositions of 1,602 shares on 06/12/2026 for $32,280.30 and 909 shares on 06/15/2026 for $18,184.82. The filing also lists restricted stock issuances of 1,248 shares on 02/08/2026 and 3,754 shares on 02/27/2026.
Form 144 is a notice of proposed sale under securities law; the entries shown report the number of shares and dollar amounts for the disclosed transactions.
USANA Health Sciences chief commercial officer Brent Neidig reported two open-market sales of common stock. On June 12, he sold 1,602 shares at $20.15 per share. On June 15, he sold an additional 909 shares at $20.005 per share. After these transactions, he directly holds 5,002 shares of USANA common stock.
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a Form 144 notice related to proposed sales of Common shares of USNA. The excerpt lists restricted stock items dated 02/07/2026 (220 shares) and 02/08/2026 (689 shares), and a sale of 1,602 shares on 06/12/2026 with a reported aggregate value of $32,280.30.
USANA Health Sciences chief people officer Paul A. Jones sold 5,561 shares of company common stock in an open-market transaction at $18.50 per share. Following this sale, he reported holding no shares of USANA common stock directly.
Paul A. Jones reported a sale of Common Stock: 6,813 shares on 05/28/2026 for $129,106.35. The filing also lists restricted stock issuances from the issuer: 672 shares on 02/07/2026, 1,642 shares on 02/08/2026, and 3,247 shares on 02/27/2026. The report names Morgan Stanley Smith Barney LLC as the broker/dealer.
USANA Health Sciences director John Turman Fleming sold shares in the company. He completed an open-market sale of 2,450 shares of USANA common stock at a price of $17.93 per share. After this transaction, he directly holds 4,230 shares, indicating he retains a meaningful personal stake in the company despite the sale.
USANA Health Sciences executive Paul A. Jones, the company’s Chief People Officer, sold 6,813 shares of Common Stock in an open-market transaction at a price of $18.95 per share.
After this sale, Jones directly holds 5,561 shares of USANA stock, and no derivative positions are shown in this filing.